What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to report Amgen's unaudited financial results for the third quarter and the first nine months of 2023, and its financial position as of September 30, 2023. It includes a press release that details these results and provides reconciliations for non-GAAP financial measures.

What are non-GAAP financial measures and why does Amgen use them?

Non-GAAP financial measures are financial metrics that exclude certain items from the GAAP (Generally Accepted Accounting Principles) results. Amgen uses them, such as non-GAAP earnings per share and operating income, to provide investors with additional insights into the company's ongoing operational performance. They are intended to facilitate comparisons of results across different periods by excluding items like acquisition-related expenses and restructuring costs, which can be volatile or infrequent.

What types of expenses are excluded from Amgen's non-GAAP financial measures?

Amgen excludes several types of expenses from its non-GAAP calculations. These primarily include acquisition-related expenses (like amortization of acquired intangibles), net charges from restructuring and cost-saving initiatives, and certain other items deemed outside the ordinary course of business, such as specific investment gains/losses, impacts from nonstrategic divestitures, and certain legal settlement costs. They also exclude certain costs related to debt financing for the Horizon Therapeutics acquisition.

Is Free Cash Flow (FCF) a GAAP or non-GAAP measure for Amgen?

Amgen calculates Free Cash Flow (FCF) by subtracting capital expenditures from operating cash flow, with both components determined in accordance with GAAP. While FCF is not a non-GAAP measure itself, the company highlights it as an important indicator of its liquidity and ability to generate cash, often analyzed alongside its GAAP and non-GAAP earnings.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on October 31, 2023, to report its unaudited financial results for the third quarter and first nine months of 2023, along with its financial position as of September 30, 2023. The report primarily includes a press release detailing these results and provides reconciliations for non-GAAP financial measures. Investors should note that Amgen utilizes non-GAAP metrics, such as non-GAAP earnings per share and operating income, to offer a more comparable view of ongoing business performance across periods, excluding items like acquisition-related expenses, restructuring costs, and certain other non-recurring items. The company also highlighted Free Cash Flow (FCF) as a key liquidity measure. Management believes these non-GAAP adjustments and FCF provide valuable insights into operational performance and financial health, facilitating a better understanding of the company's core business activities and its ability to generate cash. Investors are encouraged to review the provided press release for the detailed financial figures and the specific reconciliations between GAAP and non-GAAP measures.

Key Highlights

1Amgen announced its third quarter and year-to-date 2023 financial results via an 8-K filing on October 31, 2023.
2The filing includes a press release furnishing the company's unaudited operating results and financial position as of September 30, 2023.
3Amgen presented non-GAAP financial measures, including non-GAAP earnings per share, operating income, and net income, to provide a clearer view of ongoing business performance.
4Key excluded items for non-GAAP calculations include acquisition-related expenses, restructuring costs, and certain investment/divestiture-related items.
5Free Cash Flow (FCF) was highlighted as an important measure of the company's liquidity.
6Management uses non-GAAP measures to enhance comparability and evaluate performance, believing they offer useful supplementary information to investors.
7The information furnished in the 8-K is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934.

AMGEN INC 8-K Report, Financial Results (Oct 31, 2023)

Summary

Key Highlights

Frequently Asked Questions